The proof of concept for two-photon activated photodynamic therapy has already been achieved for cancer treatment but the efficiency of this approach still heavily relies on the availability of photosensitizers combining high two-photon absorption and biocompatibility. In this line we recently reported on a series of porphyrin-triphenylamine hybrids which exhibit high singlet oxygen production quantum yield as well as high two-photon absorption cross-sections but with a very poor cellular internalization. We present herein new photosensitizers of the same porphyrin-triphenylamine hybrid series but bearing cationic charges which led to strongly enhanced water solubility and thus cellular penetration. In addition the new compounds have been found localized in mitochondria that are preferential target organelles for photodynamic therapy. Altogether the strongly improved properties of the new series combined with their specific mitochondrial localization lead to a significantly enhanced two-photon activated photodynamic therapy efficiency.

两光子活化的光动力疗法的概念证明已经用于癌症治疗，但是这种方法的效率仍然在很大程度上取决于结合了高光子吸收和生物相容性的光敏剂的可用性。在这方面，我们最近报道了一系列卟啉-三苯胺杂化物，这些杂化物表现出高的单线态氧产生量子产率以及高的双光子吸收截面，但细胞内在化非常差。我们在此介绍了相同卟啉-三苯胺杂化系列的新型光敏剂，但带有阳离子电荷，从而导致水溶性大大增强，从而促进了细胞渗透。另外，已经发现新化合物位于线粒体中，其是光动力疗法的优选靶细胞器。